$RIGL.. $103m cash runway thru 3Q17. Two P3 fostamatinib trials in ITP, P2s in IgAN & in AI hemolytic anemia (no approved tx) all data by EY16. (H/t @mgoodma)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.